Glucagon-Like Peptide-1 Receptor Agonists and Risk of Gastrointestinal Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used for glucose lowering and weight-loss. However, their association with gastrointestinal cancer remains uncertain. This meta-analysis assesses the risk of gastrointestinal cancer in patients treated with GLP-1 RAs.